SNP | Genotype | Casesa
| Controlsa
| Relative riskb
| Relative riskc
|
---|
SNP1 | T/T | 450 (35.3) | 556 (33.9) | 1.00 (Reference) | 1.00 (Reference) |
| T/A | 575 (45.1) | 762 (46.4) | 0.94 (0.79–1.11) | 0.94 (0.79–1.12) |
| A/A | 249 (19.5) | 324 (19.7) | 0.95 (0.77–1.17) | 0.94 (0.75–1.17) |
SNP2 | A/A | 1158 (90.5) | 1495 (90.5) | 1.00 (Reference) | 1.00 (Reference) |
| A/C | 118 (9.2) | 154 (9.3) | 1.00 (0.77–1.30) | 1.02 (0.78–1.34) |
| C/C | 4 (0.3) | 3 (0.2) | 1.64 (0.36–7.45) | 2.07 (0.42–10.26) |
SNP3 | G/G | 455 (35.8) | 553 (34.3) | 1.00 (Reference) | 1.00 (Reference) |
| G/A | 570 (44.9) | 755 (46.8) | 0.99 (0.83–1.17) | 0.99 (0.83–1.18) |
| A/A | 245 (19.3) | 306 (19.0) | 1.03 (0.83–1.28) | 1.03 (0.82–1.29) |
SNP4 | A/A | 164 (12.7) | 189 (11.0) | 1.00 (Reference) | 1.00 (Reference) |
| A/C | 565 (43.9) | 759 (44.0) | 0.88 (0.69–1.12) | 0.87 (0.68–1.12) |
| C/C | 559 (43.4) | 778 (45.1) | 0.86 (0.67–1.09) | 0.85 (0.66–1.09) |
SNP5 | C/C | 970 (75.7) | 1207 (73.1) | 1.00 (Reference) | 1.00 (Reference) |
| C/A | 292 (22.8) | 417 (25.2) | 0.87 (0.73–1.04) | 0.86 (0.72–1.04) |
| A/A | 20 (1.6) | 28 (1.7) | 0.81 (0.45–1.47) | 0.81 (0.44–1.50) |
-
a Data presented as n (%). Numbers may not add to totals due to missing genotype data. b Relative risks are crude odds ratios from conditional logistic regression models (95% confidence interval). c Relative risks (95% confidence interval) are from conditional logistic regression models adjusted for age at menarche (< 12 years, 12 years, 13 years, > 13 years), age at menopause (≤ 45 years, 46–50 years, 51–60 years), first-degree family history of breast cancer (yes/no), personal history of benign breast disease (yes/no), weight gain since age 18 (< 5 kg, ≥ 5 to < 20 kg, ≥ 20 kg), body mass index at age 18 (continuous), age at first birth/parity (nulliparous, one to four children/age at first birth ≤ 24 years, one to four children/age at first birth > 24 years, five or more children/age at first birth ≤ 24 years, five or more children/age at first birth > 24 years), and duration of postmenopausal hormone use (premenopausal, never, past user < 5 years duration, past user ≥ 5 years duration, current user < 5 years duration, current user ≥ 5 years duration).